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Calmodulin inhibitor trifluoperazine in combination with doxorubicin
induces the selection of tumour cells with the multidrug resistant
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Summary Trifluoperazine (TFP) is effective in modulating DNA damage/repair in doxorubicin (DOX)
treated cells. In the present study we have characterised the resistance phenotype of parental sensitive L1210
mouse leukaemia cells (L1210/S) adapted to grow in the presence of 0.017 ltm DOX + 5 gsM TFP (L1210/DT).
Although with prolonged exposure, 0.017 LM DOX alone produced <35% cell kill in L1210/S cells, similar
cytotoxicity was achieved at 0.43 ytM DOX in L1210/S cells selected in the presence of 0.017 JLM DOX + 5 fM
TFP. L1210/DT cells were > 30-fold resistant to DOX following a 3 h drug exposure in a soft agar colony
assay. In contrast, DOX sensitivity in cells adapted to grow in 5 fiM TFP alone was comparable to L1210/S
cells. Resistance to other inhibitors of topoisomerase II in L1210/DT cells was > 30-fold to epotoside and
>6-fold to amsacrine. The levels of the 170 kDa and 180 kDa isoforms of topoisomerase II in an immunoblot
were comparable between the L1210/S and L1210/DT cells. Cross resistance to vincristine in the L1210/DT
cells was accompanied by the overexpression of plasma membrane P-glycoprotein. Although a 1.5-2-fold
decrease in accumulation of etoposide and DOX was observed in the L1210/DT cells, drug levels for
equivalent DNA damage in the alkaline elution assay were >5-fold higher in the L1210/DT versus L1210/S
cells. No abrogation in the modulating effects of TFP on DOX, VP-16 or amasacrine induced cytotoxicity was
apparent in the L1210/DT cells. Results suggest that: (a) TFP in combination with low concentrations DOX
can induce the selection of cells with the multidrug resistant phenotype; and (b) characteristics of cells selected
for resistance to DOX or DOX plus TFP are comparable.
The antitumour agent doxorubicin (DOX), an anthracycline
antibiotic interacts with multiple cellular targets which pos-
sibly govern its cytotoxic activity (Riggs, 1992). Although the
clinical efficacy of DOX has been documented in a number
of tumour types, the development of resistance with repeated
courses of chemotherapy is not uncommon (Riggs, 1992).
This form of resistance which is 'acquired' has been charac-
terised in a variety of model systems selected by prolonged
exposure to DOX (Endicott & Ling, 1989). Since a precise
target governing antitumour effects of DOX have not been
defined, the mechanisms of resistance have been equally
elusive. However, the identification of overexpression of
membrane P-glycoprotein (PGP) responsible for cellular
efflux of drug and/or alterations in topoisomerase II (TOPO
II) in model systems, underscore the significance of these
putative targets (Endicott & Ling, 1989; Ganapathi et al.,
1989).
The search for agents to modulate chemosensitivity of
tumours is of potential importance. Characteristics of agents
which modulate the multidrug resistant (MDR) phenotype
have been recently reviewed (Ford & Hait, 1990). In general,
the interaction of the modulating agents with P-glycoprotein
resulting in increased drug accumulation has been an
accepted mechanism of action (Endicott & Ling, 1989; Ford
& Hait, 1990). While MDR modulating agents invariably
increase drug accumulation, a role for such alterations
directly contributing to a cytotoxic response are dependent
on the type of antitumour agent (Ganapathi et al., 1991b).
Since we originally reported (Ganapathi & Grabowski,
1983) the modulation of DOX cytotoxicity by the calmodulin
inhibitor trifluoperazine (TFP), our subsequent studies have
demonstrated that the effect of TFP in modulating cytotox-
icity of DOX and other inhibitors of topoisomerase II is
usually not correlative with the increase in cellular drug levels
(Ganapathi et al., 1989; Ganapathi et al., 1991b). Prolonged
vs pulse exposure to DOX plus TFP is also significantly more
cytotoxic than DOX alone in both wild-type or resistant
tumour cells (Ganapathi et al., 1984). Since the use of MDR
modulating agents in initial treatment regimens to prevent
emergence of drug resistance has been suggested (Salmon et
al., 1991), we have pharmacologically and biochemically
characterised L1210 mouse leukaemia cells selected for resis-
tance to a combination of DOX plus TFP. Results from this
study suggest that while mechanisms of resistance are
qualitatively similar to that observed with cells selected for
resistance to DOX alone, minimally cytotoxic concentrations
of DOX alone in combination with non-cytotoxic levels of
TFP can induce the selection of > 30-fold DOX-resistant
cells with the MDR phenotype.
Materials and methods
Ascites from a mouse bearing L1210 lymphoid leukaemia
was used to establish the in vitro cell line (Ganapathi &
Grabowski, 1988). Cells were routinely cultured in RPMI
1640 supplemented with 2 mM L-glutamine, 25 mM N-2-
hydroxyethylpiperazine-N-ethanesulfonic acid buffer (M.A.
Bioproducts, Walkersville, Maryland), 10% foetal bovine
serum (Sterile Systems, Logan, Utah) and 10lM 2-
mercaptoethanol.
The parental sensitive L1210 cell line (L1210/S) was
adapted to grow for 24 weeks in the presence of 0.017fLM
DOX plus 5ILM TFP for selection of the resistant subline
(L1210/DT). Cell kill of L1210/S cells in a soft-agar
colony assay following short-term (3 h) and prolonged
exposure (96 h) to 0.017LM DOX alone was <10% and
<35% respectively. Following this selection period, cells for
experiments outlined were maintained in the absence of DOX
plus TFP. Another separate subline was simultaneously
developed from the parental cells (L1210/S) by continuous
exposure for 24 weeks to SiM TFP alone (L1210/5,AM TFP).
Treatment conditions for isolation of resistant sublines
involved exposure of cells to the selecting agent(s) for 5 days
followed by regrowth in medium without selection pressure
for 2 days in repetitive cycles.
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Cytotoxicity in vitro
Cytotoxic response to doxorubicin (DOX), etoposide (VP-
16), vincristine (VCR) or amsacrine (m-AMSA) in the sen-
sitive and resistant sublines was determined by a soft agar
colony assay (Ganapathi & Grabowski, 1988). Briefly sen-
sitive or resistant sublines were treated for 3 h with DOX,
VP-16, VCR, or m-AMSA in the absence or presence of 5SM
TFP at 37°C in a humidified 5% CO2 plus 95% atmosphere.
Control and treated cells were subsequently washed with
drug-free medium and plated in 35 x 10 mm Petri dishes,
incubated at 37°C in humidified 5% CO2 plus 95% air
atmosphere for 96 h and colonies (>50 cells) counted as
described earlier (Ganapathi & Grabowski, 1988). The col-
ony forming efficiency of the sensitive and the sublines
selected for resistance to DOX plus TFP or TFP alone was
approximately 33%.
Drug accumulation and retention in vitro
Log-phase cultures of L1210/S and L1210/DT cells were
treated in vitro at 37°C in a humidified 5% CO2 plus 95% air
atmosphere with doxorubicin or [3H]-VP-16 (>95% pure by
high performance liquid chromatography) in the absence or
presence of 5mM TFP. Cells following treatment were washed
2-3 times using cold (4°C) 0.85% sodium chloride solution
and levels of DOX and VP-16 quantified by spectro-
fluorimetry (Ganapathi & Grabowski, 1988) and liquid scin-
tillation respectively (Kamath et al., 1991).
Experiments on drug retention were carried out by
preloading cells with the IC50 of DOX ± 5iM TFP for 3 h.
Cells were subsequently centrifuged, washed and resuspended
in medium in the absence of 5;LM TFP. Samples were re-
trieved at 15-30 min intervals over 120 min and cellular
DOX levels quantified as described earlier (Ganapathi &
Grabowski, 1988).
Table I Cytotoxic effects of doxorubicin (DOX) in L1210/S and
L12I0/5IM TFP cells
Doxorubicin (1lM)a Survival (% of Control)b
L1210/S L120/5liMTFP
0.017I1M 98 94
0.017,LM+ 5gAM TFP 97 92
0.086jLM 60 54
0.086 M + 5tLM TFP 52 42
0.172ftM 13 10
0.172tiM+ 5pM TFP 12 5
aCells were treated with doxorubicin in the absence or presence of
5tLM TFP for 3 h at 37'C.
bSurvival was based on inhibition of colony formation compared to
the untreated control in a soft-agar colony assay. The data are the
mean value from triplicate Petri-dishes in a representative
experiment. The range between replicate Petri-dishes was <10%.
Drug induced DNA damage by alkaline elution
Damage to DNA induced by DOX or VP-16 in the absence
or presence of 5fM TFP was determined by alkaline elution
under deproteinising conditions (Kohn et al., 1981). Details
of the method for determining DNA single-strand breaks
(DNA-SSB) by DOX and VP-16 have been previously de-
scribed (Ganapathi et al., 1991a; Kamath et al., 1991). Elu-
tion with tetrapropylammonium hydroxide-EDTA, 0.1%
SDS, pH 12.1 was carried out at a flow rate of 0.03-0.04 ml
min-' with fractions collected at 3 h intervals over 18 h for
DOX treated cells, and a flow rate of 0.12-0.16mlmin-'
with fractions collected at 5min intervals over 30min for
VP-16 treated cells.
Immunoblottingfor topoisomerase II
Nuclear extracts from log phase cultures of L1210/S and
L1210/DT cells were prepared with 0.35 M NaCl as
4-0
' I A o
.- - a .... a.. ..a 8
0
.01 0.1 1
0 Doxorubicin (>LM)
0-1I
2 100
en)
801-
601-
40
20
0.01 0.1
m-AMSA (,UM)
4
2
O L1210/S
0O * L1210/S + 5,LMTFP
O L1210/DT
W0 * L1210/DT + 5 FM TFP
:0
to aaa a aa a a a a a u a
0. . ., , -, . .
0.01 0.1 1 10 10C
VP-16 (p.M)
100
801-
60
401-
20
0L
0..001 0.01 0.1 1 10
Vincristine (,UM)
Figure 1 Cytotoxic effects of DOX, VP-16, m-AMSA, and VCR in the absence or presence of 5 JM TFP in L1210/S and
L1210/DT cells treated for 3 h. Survival is based on colony counts. Cells were plated at a density of 5 x 103 cells/35 x 10 mm Petri
dish and colony count (mean ± standard error) in the untreated control was 1645 ± 474 corresponding to a colony forming
efficiency of 33%. Each point is the mean ± standard error of triplicate experiments.
I I I a Im a Ia I Ia I a I Ia Imama I a maa a amaaa a aa
0
T-- 0-6-V
-L-
1RESISTANCE INDUCED WITH DOX PLUS TFP 1205
200
180
u. 160
a)
) 140
tD
0
r' 120
.2 100
.0
80
0
x
o 60
0
0, 40
c
(1)
o
x
0
0
CD
S--DT'-S--DT- -S- DT-
200.172 F±M DOX 0.86 FM DOX 3.44 FLM DOX
180- 3 Hour uptake b
160- M TFP
140 - * +5 FM TFP
120 I
S DT S DT
80.172 jLM DOX 0.86 RM DOX
1 Hour uptake
70
a) o60
0
co 50
a-
CL 40
30
20
E
0
c 10
0
o-5 F.M TFP
*+5pM TFP
i S DT
3.44 FLM DOX
c
S- -DT- -S- -DT- S- DT-
5FLMVP-16 10FMVP-16 40pFMVP-16
Figure 2 Effect of TFP on cellular accumulation of DOX at I h
a, and 3 h b, and VP-16 at 1 h c, in L1210/S and L1210/DT cells.
Values are means of duplicate determinations from at least trip-
licate experiments.
previously described (Ganapathi et al., 1989). Protein content
in nuclear extracts was determined by the bicinchoninic acid
method (Smith et al., 1985). Gel electrophoresis by SDS-
PAGE was carried out as originally described by Laemmli
(1970). Briefly, protein (50 1fg) from nuclear extracts was run
on gels using a 4% stacker and 5% resolving gel. The
nitrocellulose following electroblotting (Towbin et al., 1979)
of the gel was probed with polyclonal antiserum FHD-29
which simultaneously recognises the 170kDa and 180kDa
isoforms of topoisomerase II. The binding of rabbit antisera
to TOPO II was detected using goat anti-rabbit alkaline
phosphatase conjugated antibody and 5-bromo-4-chloro-3-
indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) as
the substrate for colour development.
Detection ofphosphorylated P-glycoprotein
Log-phase cultures of L1210/S and L1210/DT cells in phos-
phate free RPMI 1640 supplemented with 2 mM L-glutamine
and 10% foetal bovine serum were labelled for 2-3 h with
carrier-free [32P]orthophosphoric acid (0.83 mCiml-') at 37°C
in a 95% air plus 5% CO2 atmosphere (Ganapathi et al.,
1991a). Cells were pelleted, lysed and PGP immunoprecipitat-
ed with C-219 monoclonal antibody (Centocor Inc., Malvern,
Pennsylvania) as previously described (Anderson & Blobel,
1983; Ganapathi et al., 1991a). Samples were electrophoresed
on 5% SDS-polyacrylamide gels. The gels were fixed, dried
and autoradiographed at - 70°C using preflashed X-OMAT
AR film (Kodak Laboratories, Rochester, NY).
Results
The sensitive (L1210/S) and resistant sublines (L1210/DT &
L1210/5gM TFP) proliferated in vitro as single cell suspension
cultures with a doubling time of approximately 10-12 h.
Based on a periodic determination of the cytotoxic effects of
DOX in a soft-agar colony assay, the L1210/DT cells were
stably resistant in the absence of DOX plus TFP for at least
3 months (200 doublings) during in vitro culture.
The results with Li210/S and L1210/DT cells evaluating
the cytotoxic effects of drugs that belong to the MDR
phenotype and/or inhibit topoisomerase II in the absence or
presence of 5 gM TFP are outlined in Figure 1. Based on the
IC50 (concentration required to reduce colony forming ability
by 50% compared to the untreated control), following 3 h
drug treatment the L12IO/DT cells were 30-fold resistant to
DOX and VP-16, 6-fold resistant to m-AMSA and complete-
ly resistant to VCR (<20% kill at 0.1-2.O0I1M) compared to
similarly treated L1210/S cells. Further, while the modulation
of DOX (2- to 20-fold), VP-16 (2- to 10-fold), and m-AMSA
(3-fold) cytotoxicity by 5 gLM TFP was readily apparent in the
L1210/DT vs L1210/S cells, the effects on VCR toxicity were
modest in the L12IO/S cells (2-fold) and minimal in the
L1210/DT cells. In contrast to the DOX resistance observed
in L1210/DT cells selected with the combination of
DOX + 5 IM TFP, as shown in Table I, no apparent resis-
tant to DOX was observed in cells adapted to grow in the
presence of 5 IfM TFP alone for time periods comparable to
selection of the L1210/DT cells.
The effect of 51M TFP on the accumulation of DOX and
VP-16 in the L12IO/S and L1210/DT cells is shown in Figure
2. Accumulation of DOX in the L1210/S and L1210/DT cells
was time dependent (1 h<3 h) and cellular DOX levels in
L1210/DT cells were 10-50% lower than in similarly treated
L12IO/S cells. Although the effect of 5 gM TFP on DOX
accumulation in Li210/S cells was not remarkable, cellular
DOX levels in L12IO/DT cells were 30-100% higher in the
presence vs absence of 5lM TFP. The magnitude of decrease
in accumulation of VP-16 in L1210/DT vs L1210/S cells was
comparable to that observed with DOX. In contrast,
although 5YM TFP increased VP-16 levels 20-50% in the
L1210/S cells, no effect on VP-16 accumulation with L1210/
DT cells was observed. Steady state levels of VP-16 are
achieved in 1 h. However, in the case of doxorubicin, steady
state levels are generally not achieved within 3 h. The
significant increase in accumulation of VP-16 in sensitive
cells, due to trifluoperazine, is apparent only at 40tM which
is far in excess of the range used for the cytotoxicity
experiments. The effect of trifluoperazine on increasing cel-
lular accumulation of VP-16 in sensitive, but not in
doxorubicin-resistant sublines has been previously reported
by us (Kamath et al., 1991).
The cellular retention of DOX in L121O/S and L1210/DT
cells is outlined in Figure 3. The experimental strategy of
using different concentrations of doxorubicin for the L1210/S
vs Li2I1/DT cells for treatment with or without
trifluoperazine was carried out in order to achieve com-
parable cellular doxorubicin levels prior to retention
experiments. The 3 h uptake followed by retention was car-
ried out in order to mimic the protocol used for cytotoxicity
experiments. In L1210/S cells treated with the IC50 of DOX
in the absence or presence of 5 gM TFP, DOX retention was
50-70% of that initially accumulated and represented app-
roximately 5 ng DOX 10-6 cells. In contrast, while DOX1206 N. KAMATH et al.
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Figure 3 Effect of TFP on cellular retention of DOX in L1210/S
a, and L1210/DT cells b, treated with the IC5' concentration of
DOX in the absence or presence of 5 gM TFP. Each point is the
mean value of replicate determinations from at least duplicate
experiments. Cellular DOX levels are expressed in ng 10-6 cells
(-) and as a percentage (---) of drug initially accumulated.
levels in L1210/DT cells treated with ICm of DOX plus 5 pLM
TFP was 2-fold lower than in the cells treated with ICs of
DOX alone, drug retention expressed as a percentage of that
initially accumulated was comparable with both treatments.
The effect of TFP on DOX and VP-16 induced DNA-SSB
in L1210/S and L1210/DT cells is shown in Figure 4. Induc-
tion of DNA-single strand breaks by equimolar doses of
DOX and VP-16 were 2-4-fold lower in L1210/DT vs
L1210/S cells. However, in both L1210/S and L1210/DT
cells, DNA strand breaks induced by DOX or VP-16 were
potentiated in the presence of 5 gM TFP.
The levels of the TOPO II using antisera specific for
170 kDa and 180 kDa isoforms of TOPO II are shown in
Figure 5. The results show that the levels of the two isoforms
of TOPO II (170 kDa and 180 kDa) in the L1210/S and
L1210/DT cells are comparable.
The amount of P-glycoprotein in L1210/S and L1210/DT
cells following metabolic labelling with [32P]orthophosphoric
acid is shown in Figure 6. Results demonstrate the absence of
any phosphorylated PGP in L1210/S cells which is consistent
with the lack of overexpression of PGP in these cells
(Ganapathi et al., 1991a). However, in the L1210/DT cells,
the overexpression and phosphorylation of PGP is readily
apparent.
Discussion
Drug resistance in the chemotherapy of cancer continues to
be a constant challenge. Although mechanisms of resistance
could be specific for a given class of agents, expression of
resistance to drugs with different mechanistic basis for
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Figure 4 Modulation of DOX a, or VP-16 b, induced DNA-SSB
by TFP in L1210/S and L1210/DT cells treated for 1 h. Values
are mean ± s.e. from at least triplicate experiments.
cytotoxicity has been a subject of considerable interest
(Endicott & Ling, 1989). The phenomenon of broad cross-
resistance referred to as the multidrug resistant phenotype is
typified by the overexpression of a 150-180 kDa membrane
glycoprotein, termed P-glycoprotein which is responsible for
efflux of accumulated drug (Endicott & Ling, 1989).
Numerous hydrophobic compounds have been demonstrated
to modulate MDR, and an accepted mechanism for their
efficacy is based on interaction with PGP (Endicott & Ling,
1989; Ford & Hait, 1990).
Since the occurrence of resistant tumour cells is not
uncommon, the use of the modulating agents in combination
treament has been suggested to prevent emergence of multi-
drug resistant cells (salmon, et al., 1991). Among the modula-
tion agents, verapamil has been the most widely studied
(Endicott & Ling, 1989; Ford & Hait, 1990). Our previous
studies have focussed on trifluoperazine as a modulating
agent and while its efficacy in affecting vinca alkaloid
cytotoxicity was dependent on enhancing cellular drug levels,
the potentiation of cytotoxicity with inhibitors of TOPO II
was not correlative with corresponding increases in drug
accumulation (Ganapathi et al., 1991b).
In this report, we demonstrate that the inclusion of TFP
with minimally cytotoxic concentrations of DOX can induce
the selection of cells with the MDR phenotype. While the
L1210/DT cells were selected following exposure of L1210/S
cells to 0.017 7 M DOX + 5 LM TFP, to achieve comparable
levels of resistance, Li210/S cells in previous experiments had
to be progessively exposed with up to 20-fold higher concent-
rations of DOX (Ganapathi & Grabowski, 1988).
The results in Figure 1 demonstrate that the L1210/DT
cells are cross resistant to inhibitors of TOPO II and vincris-
tine. No cross-resistance to the topoisomerase I inhibitor
camptothecin, was observed (data not shown). The expres-
sion of resistance to VCR in L1210/DT cells was not surpris-
ing based on the overexpression of PGP and this is consistent
with the relationship between overexpression of PGP and
VCR resistance (Ganapathi et al., 1991b). The reduced
accumulation and retention of DOX in the L1210/DT cells
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Figure 5 Detection of TOPO II in L121O/S and L1210/DT cells.
Each lane contained 50 ,g of protein from nuclear extracts.
suggests a role for PGP overexpression. However, the data in
Figure 3 simulating treatment conditions for cell survival
data in Figure 1 suggest the following: (a) At the IC50 of
DOX alone, DOX retention at near steady state is 5-fold
higher in the L1210/DT vs L1210/S cells; (b) In L1210/DT
cells treated with the IC50 of DOX ± 5 gM TFP, the percent
of DOX retained is comparable; and (c) cellular DOX levels
for equivalent kill in L1210/DT cells were>2-fold higher in
absence vs presence of TFP. The requirement of higher DOX
levels for equivalent cell kill is also apparent in the data on
induction of DNA-SSB by DOX and VP-16 (Figure 4). The
reduced induction of DNA-SSB is not correlative with cor-
responding changes in drug levels and may be related to
selective alterations in drug stimulated DNA cleavage activity
without reduction in levels (Figure 5) or unknotting activity
of P4 DNA (data not shown) of TOPO II. The requirement
of low cellular DOX levels for equivalent DNA-SSB or cell
kill in the presence vs absence of TFP is comparable to our
observations in other model systems of DOX resistant cells
(Ganapathi et al., 1991a) and possibly not related to cellular
drug redistribution.
Our previous studies on the exposures of sensitive or
DOX-resistant cells with 5 LM TFP following DOX treat-
ment demonstrated enhanced chromosomal aberrations and
cell kill suggestive of inhibition in DNA repair (Ganapathi et
al., 1990). It thus may be possible that the induction of
resistance following selection with a lower concentration of
DOX in the presence of TFP is a consequence of alterations
in DNA repair. The reduced TOPO II mediated DNA strand
breaks and overexpression of PGP in L1210/DT cells are
different from other reports using a combination of DOX
and verapamil, since in these cells no overexpression of PGP
was observed, and alterations in TOPO II included a
decrease in both levels and catalytic activity (Bellamy et al.,
1990; Chen et al., 1990). The absence of DOX resistance in
cells adapted to grow in TFP alone is comparable to that
reported with verapamil alone (Twentyman et al., 1990),
demonstrating that these mechanistically different agents
77-
1 2
Figure 6 Detection of phosphorylated PGP in L1210/S (lane 1)
and L2120/DT (lane 2). Data from a representative experiment
are shown.
based on pharmacological effects may not affect putative
targets of DOX cytotoxicity when used alone. Further, the
continued ability of TFP to modulate DOX resistance in
L1210/DT cells, while surprising, suggest that targets
involved in modulation are possibly not compromised.
In summary, results from this study demonstrate that non-
cytotoxic concentrations of 5fLM TFP in combination with
0.017 fLM DOX can induce selection of > 30-fold DOX-
resistant cells with the MDR phenotype. The mechanisms of
resistance which involve alterations in TOPO II mediated
DNA strand breaks and PGP overexpression in cells selected
with DOX + TFP are comparable to that observed in cells
following selection with DOX alone. Although a potentiation
in the development of resistance clinically needs to be
carefully assessed, a combination of DOX plus verapamil in
tumour bearing mice has also been suggested to lead to the
rapid development of resistance (Formelli et al., 1988).
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